StockData

Compugen vs Sutro Biopharma

CGEN and STRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CGEN and STRO compare

Compugen grew revenue faster over the last twelve months (161% versus −56.3% for Sutro Biopharma).

Compugen keeps more of each dollar of sales as profit, with a net margin of 48.6% compared with −395% at Sutro Biopharma.

Compugen scores higher on the StockData Score (12 against 7 for Sutro Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCGENSTRO
Size and price
Market cap–$170M
Share price$2.09$10.26
Change, 1 year25.1%27.3%
Change, 5 years−55.6%−94.2%
Beta (5Y)1.602.21
Employees2137
StockData Score
Total score12 (better)7
Valuation score01 (better)
Growth score3 (better)1
Performance score4 (better)0
Health score55
Dividend score00
Valuation
P/S–3.7×
Growth
Revenue growth (TTM)161% (better)−56.3%
Revenue growth, 5Y average105% (better)19.1%
Profitability
Gross margin87.3%–
Operating margin43.1% (better)−320%
Net margin48.6% (better)−395%
FCF margin43.1%–
Return on equity50.9%–
Return on invested capital117%–
Financial health
Debt / equity0.00–
Current ratio5.72 (better)3.32
Altman Z-score–−8.74
Piotroski F-score7 (better)2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–99.4%
Held by insiders0.43%6.1%
Insider net buying, 12 months−$126K$0 (better)
Short interest, % of float2.7%14.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.